Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Share-based Compensation (2019 - 2025)

Cyclerion Therapeutics has reported Share-based Compensation over the past 7 years, most recently at $118000.0 for Q3 2025.

  • Quarterly results put Share-based Compensation at $118000.0 for Q3 2025, down 14.49% from a year ago — trailing twelve months through Sep 2025 was $468000.0 (down 22.77% YoY), and the annual figure for FY2024 was $625000.0, down 41.42%.
  • Share-based Compensation for Q3 2025 was $118000.0 at Cyclerion Therapeutics, up from $114000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for CYCN hit a ceiling of $2.5 million in Q4 2021 and a floor of $103000.0 in Q4 2023.
  • Median Share-based Compensation over the past 5 years was $379000.0 (2023), compared with a mean of $942157.9.
  • Biggest five-year swings in Share-based Compensation: tumbled 90.84% in 2023 and later grew 18.45% in 2024.
  • Cyclerion Therapeutics' Share-based Compensation stood at $2.5 million in 2021, then tumbled by 55.87% to $1.1 million in 2022, then tumbled by 90.84% to $103000.0 in 2023, then grew by 18.45% to $122000.0 in 2024, then decreased by 3.28% to $118000.0 in 2025.
  • The last three reported values for Share-based Compensation were $118000.0 (Q3 2025), $114000.0 (Q2 2025), and $114000.0 (Q1 2025) per Business Quant data.